"How am I supposed to pay my rent?"
I had no answer. The irony of practicing medicine in the wealthiest country in the history of the world is that I could measure drug concentrations in his blood and even sequence the genome of his TB bacilli at the click of a button, but could not help him with his rent, which costs far less than either test.
TB has been described as the shadow of misery. Our biomedical response, for all its brilliance, ends up chasing the shadow and not the person casting it.
At conferences, it may appear as if the end of TB is just awaiting the arrival of a new drug, test, or vaccine. Indeed, our grant applications and buzzy press releases often signal as much. But the inconvenient truth, written plainly in the mortality curves, is that TB had already begun its retreat in the wealthy world before we had any effective tests or treatments. Death rates fell as people ate better, worked shorter hours, and moved out of airless tenements. The bacillus did not surrender to medicine alone. It receded as life got less brutal.
We have spent the decades since forgetting that lesson. We have bet, and bet heavily, on the biomedical paradigm — on the next diagnostic, the shorter regimen, the elusive vaccine. These are good bets, and I have placed many of them myself. But a disease that lives in the lungs is born in the conditions of a life: in undernutrition, in crowded and unventilated rooms, in the soot of the air, in the precariousness of being poor. We keep treating the cough and ignoring the world that produced it.
Although we routinely call TB a disease of poverty, we seem to design all our interventions downstream of this principal driver. For all its biological tricks and complexity, TB is ultimately a predictable disease. It goes where deprivation goes, and it leaves where deprivation lifts. When TB flares, it is telling us something true about hunger and housing and inequality long before our other instruments register it.
When a canary dies in a coal mine, we don't just apply an oxygen mask to its beak; we get the miners to safety.
This is the difference between public health and social medicine. Public health counts the sick and delivers the cure. Social medicine asks why this person, in this place, got sick in the first place — and treats the answer as part of the disease. Social protection is where that conviction becomes concrete. Cash transfers keep months of catastrophic costs from turning into generational poverty. Nutritional support turns a starving patient into a healing one. There is mounting evidence that this support does not merely comfort people, it helps cure them, keeps them in treatment, and protects those around them.
What we still lack is enough rigorous, real-world evidence on how to actualize this support for those who need it the most.
That is the gap this collection exists to close. Our goal is to extend our gaze past the shadow, and to build an evidence base that informs person-centered action. In the International Journal for Equity in Health, we have opened a collection on social protection for people affected by TB, and we are inviting the people doing this work to write it down. We want the implementation studies — how these programs are designed, financed, and adapted to fragile settings. We want the country experiences, the case studies, the honest accounts of what worked and what didn't, the analyses of the politics that decide whether a program is funded or forgotten. We want the evidence that lets an advocate walk into a finance ministry and make an undeniable case.
This is our chance to finally turn from the shadow and face the person. I do want better tests and better drugs, but I also want my patient to be able to pay his rent.
--
The collection "Social Protection for TB-Affected Individuals" is open for submissions in the International Journal for Equity in Health.
Guest Editors: Pranay Sinha and Ernesto Jaramillo, with the support of Delia Boccia, Priya Shete, and Jillian Kadota.